BioWorld

Oct. 18, 2006

'Obvious' Buyout: Lilly Paying $2.1B For Cialis Partner ICOS

ICOS Corp., which through a successful joint venture with Eli Lilly and Co. commercialized the erectile dysfunction product Cialis, agreed to be acquired by Lilly in a deal valued at about $2.1 billion. (BioWorld Today) Read More

Roche, InterMune In HCV Deal With $530M Potential

Genzyme Paying $580M For AnorMED; Millennium Blinks

Memory's Phase IIa Study On Hold; Firm Raises $26M

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

US lawmakers demand that Kennedy be held accountable

BioWorld

As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...